Bildkälla: Stockfoto

Moberg Pharma Q4’21: Steady progress - Redeye

Redeye's comments on the Q4 report published earlier this morning were devoid of surprises. We will likely only make minor adjustments to our estimates. Progress is steady, and the launch is still set for 2023. We reiterate our Base case value of SEK 17 per share.

Redeye's comments on the Q4 report published earlier this morning were devoid of surprises. We will likely only make minor adjustments to our estimates. Progress is steady, and the launch is still set for 2023. We reiterate our Base case value of SEK 17 per share.
Börsvärldens nyhetsbrev
ANNONSER